Part I. Part I General Features of Brain Tumors. 1. Total Registered Number. 1) Number of Primary and Metastatic Brain Tumors

Σχετικά έγγραφα
PartⅡ Individual Analysis of Brain Tumor ( )

7KH VHQVLWLYLW\ RI UDGLRWKHUDS\ WR WLVVXH FRPSRVLWLRQ DQG LWV HVWLPDWLRQ XVLQJ QRYHO GXDO HQHUJ\ &7 PHWKRGV Guillaume Landry

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΑΝΟΙΚΤΑ ΑΚΑΔΗΜΑΪΚΑ ΜΑΘΗΜΑΤΑ

OncoNext TM Risk-Oncoscreening

Case report: Cystic meningioma

ΠΑΡΑΣΚΕΥΗ, 24 Οκτωβρίου Σεμινάριο: ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΑΓΚΡΕΑΤΟΣ

Σταδιοποίηση του καρκίνου του πνέυμονα. Καλκάνης Αλέξανδρος, Πνευμονολόγος

Χρήστος Γκόγκας Επεμβατικός Νευροακτινολόγος

Contents Part I Psychoneuroimmunology and Systems Biology Mechanisms 1 From Psychoneuroimmunology to Personalized, Systems, and Dynamical Medicine

Δεδομένα ασφάλειας του certolizumab pegol από τα αρχεία της UCB

ΙΩΑΝΝΗΣ Η. ΓΚΡΙΝΙΑΤΣΟΣ Αναπλ Καθηγητής Χειρουργικής ΕΚΠΑ. 1o Πανελλήνιο Συνέδριο Ελληνικής Εταιρείας Ήπατος-Χοληφόρων-Παγκρέατος

Infrastructure Revenue Bond for Sustainable Growth

Β.ΚΑΝΕΛΛΟΠΟΥΛΟΣ ΕΠΙΚ. ΕΠΙΜΕΛΗΤΗΣ Β Γ.Ν.Α ΚΟΡΓΙΑΛΕΝΕΙΟ ΜΠΕΝΑΚΕΙΟ Ε.Ε.Σ

Ανατοµία Βασικών Γαγγλίων. Δηµήτριος Μυτιληναίος

Ερευνητική Εργασία. A Study of Demographic Characteristics and Exposure to Known Risk Factors of Greek Patients with Actinic Keratosis (Attica Study)

Βασικές αρχές χηµειοθεραπείας στην αντιµετώπιση του µικροκυτταρικού καρκίνου (SCLC)

ΣΤΑΔΙΟΠΟΙΗΣΗ ΚΑΡΚΙΝΟΥ ΠΝΕΥΜΟΝΑ ΕΚΤΙΜΗΣΗ ΑΝΑΤΟΜΙΚΗΣ ΕΚΤΑΣΗΣ ΝΟΣΟΥ

1. Αφετηρία από στάση χωρίς κριτή (self start όπου πινακίδα εκκίνησης) 5 λεπτά µετά την αφετηρία σας από το TC1B KALO LIVADI OUT

Tissue Expression Profile of Human MAGE2D1, the Ne w Member of Melanoma Antigen2encoding Gene Family

ΑΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ ΙΑΤΡΙΚΗ ΣΧΟΛΗ. ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥ ΩΝ «Ιατρική Ερευνητική Μεθοδολογία» ΙΠΛΩΜΑΤΙΚΗ ΕΡΓΑΣΙΑ

ΚΑΡΠΟΥΖΙ / WATERMELON a b

ΠΑΝΔΠΗΣΖΜΗΟ ΠΑΣΡΩΝ ΣΜΖΜΑ ΖΛΔΚΣΡΟΛΟΓΩΝ ΜΖΥΑΝΗΚΩΝ ΚΑΗ ΣΔΥΝΟΛΟΓΗΑ ΤΠΟΛΟΓΗΣΩΝ ΣΟΜΔΑ ΤΣΖΜΑΣΩΝ ΖΛΔΚΣΡΗΚΖ ΔΝΔΡΓΔΗΑ

ΠΝΕΥΜΟΝΙΚΕΣ ΜΕΤΑΣΤΑΣΕΙΣ

ΣΠΛΑΧΝΙΚΟ ΚΡΑΝΙΟ ΜΕΤΩΠΙΑΙΟΣ ΚΟΛΠΟΣ ΚΟΓΧΟΣ ΑΝΩ ΟΦΘΑΛΜΙΚΗ ΣΧΙΣΜΗ ΙΓΜΟΡΙΟ ΑΝΤΡΟ ΗΘΜΟΕΙΔΕΙΣ ΚΑΤΩ ΡΙΝΙΚΗ ΚΟΓΧΗ. ΜΑΣΤΟΕΙΔΕΙς ΚΥΨΕΛΕΣ ΣΚΛΗΡΑ ΥΠΕΡΩΑ ΓΝΑΘΟΣ

ΑΤΣΟΑΝΟΗ ΠΑΓΚΡΕΑΣΙΣΙΔΑ. ηέξγηνο Γειαθίδεο Γαζηξεληεξνιόγνο

Αποστήματα του φάρυγγα στα παιδιά

Ενδείξεις μεταστασιεκτομής στον καρκίνο του νεφρού. Σεραφετινίδης Εφραίμ Επιμελητής Α Ουρολογική Κλινική Ασκληπιείο Βούλας Δντης: Αν. Καθ. Δ.

Discontinuous Hermite Collocation and Diagonally Implicit RK3 for a Brain Tumour Invasion Model

Group 2 Methotrexate 7.5 mg/week, increased to 15 mg/week after 4 weeks. Methotrexate 7.5 mg/week, increased to 15 mg/week after 4 weeks

Ασθενής. Μετά από μεταμόσχευση νεφρού Λεμφαδενοπάθεια Πυρετός Θετική PCR-EBV


Καρκίνος ορθού Προεγχειρητική ακτινοθεραπεία. Λουίζα Βίνη Ογκολόγος Ακτινοθεραπεύτρια Τμήμα Ακτινοθεραπείας Ιατρικό Αθηνών

Η Κυπριακή Πραγµατικότητα µέσα από Αριθµούς

Surface Mount Multilayer Chip Capacitors for Commodity Solutions

Novel Radiotherapy Approaches. Κ. Τσαμασιώτη Ακτινοθεραπευτής ΟγκολόγοςΝοσ. «ΥΓΕΙΑ» HellenicMultidisciplinary Conference on Head & Neck Cancer

< (0.999) Graft (0.698) (0.483) <0.001 (0.698) (<0.001) (<0.001) 3 months (0.999) (0.483) (<0.001) 6 months (<0.

RFA : HCC. percutaneous acetic acid injection therapy: PAIT 3 percutaneous hot water injection therapy: PHot 4 HCC HCV HCC

καρκίνος στομάχου έχει θέση η ακτινοθεραπεία; Ιωάννης Γεωργακόπουλος Ακτινοθεραπευτής Ογκολόγος

10 MERCHIA. 10. Starting from standing position (where the SIGN START ) without marshal (self start) 5 minutes after TC4 KALO LIVADI OUT

ΠΑΡΑΣΚΕΥΗ, 24 Οκτωβρίου Σεμινάριο: ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΑΓΚΡΕΑΤΟΣ

IPSJ SIG Technical Report Vol.2014-CE-127 No /12/6 CS Activity 1,a) CS Computer Science Activity Activity Actvity Activity Dining Eight-He

ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥ ΩΝ ΣΤΙΣ ΚΛΙΝΙΚΕΣ ΚΛΙΝΙΚΟΕΡΓΑΣΤΗΡΙΑΚΕΣ ΙΑΤΡΙΚΕΣ ΕΙ ΙΚΟΤΗΤΕΣ

corticobasal degeneration CBD 1968 Rebeiz

Development of a new arterial infusion chemotherapy for locally advanced breast cancer

Ataxia telengectasia and Breast cancer

ΝΕΑ ΤΑΞΙΝΟΜΗΣΗ ΤΟΥ GLEASON SCORE ΚΑΙ Η ΣΗΜΑΣΙΑ ΤΟΥ ΣΤΗΝ ΚΛΙΝΙΚΗ ΠΡΑΞΗ. Μιχαλοπούλου Μανωλούτσιου Ηλέκτρα Παθολογοανατόμος

ΕΠΙΔΗΜΙΟΛΟΓΙΚΑ ΔΕΔΟΜΕΝΑ ΠΟΥ ΑΦΟΡΟΥΝ ΤΟΥΣ ΟΓΚΟΥΣ ΤΟΥ ΕΓΚΕΦΑΛΟΥ ΣΤΗΝ ΕΛΛΑΔΑ ΚΑΙ ΔΙΕΘΝΩΣ

ΑΘΛΗΤΙΣΜΟΣ και ΥΠΕΡΤΑΣΗ

Εγκεφαλικός φλοιός. Υποδιαιρέσεις του φλοιού του εγκεφάλου. ευτερεύων αισθητικός-οπτικόςακουστικός. πληροφορίες φθάνουν στον εγκεφαλικό φλοιό

Μοριακή απεικόνιση και θεραπεία. 3 rd Nuclear Medicine dpt of AUTh I. Iakovou Assist. Professor

Influence of Flow Rate on Nitrate Removal in Flow Process

ΕΥΑΓΓΕΛΟΣ ΜΠΟΥΡΝΑΚΗΣ ΠΑΘΟΛΟΓΟΣ ΟΓΚΟΛΟΓΟΣ

- ενδείξεις μυοκαρδιακής βιοψίας-

(OR= %CI 1.266~1.418 P=0.000) 4.1cm NFA. [DOI] /j.issn

MSM Men who have Sex with Men HIV -

Εκπαιδευτικές Ημερίδες

Aluminum Electrolytic Capacitors (Large Can Type)

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ. Πτυχιακή εργασία ΑΓΧΟΣ ΚΑΙ ΚΑΤΑΘΛΙΨΗ ΣΕ ΓΥΝΑΙΚΕΣ ΜΕ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ ΜΕΤΑ ΑΠΟ ΜΑΣΤΕΚΤΟΜΗ

Ala Wai Drogue Survey

Indications for HIPEC in HPB Cancer: if any.

ΝΟΣΟΥ ΜΙΧΑΛΟΠΟΥΛΟΥ ΑΙΚΑΤΕΡΙΝΗ ΤΕ ΝΟΣΗΛΕΥΤΡΙΑ ΜΟΝ.ΕΜΦΡΑΓΜΑΤΩΝ ΚΑΜΠΙΣΙΟΥΛΗ ΕΥΣΤΑΘΙΑ ΥΠΕΥΘΥΝΗ ΓΡΑΦΕΙΟΥ ΝΟΣΗΛΕΥΤΙΚΗΣ ΕΚΠΑΙ ΕΥΣΗΣ ΓΝΑ «Ο ΕΥΑΓΓΕΛΙΣΜΟΣ»

Ασθενής 81 ετών με σοβαρή ανεπάρκεια μιτροειδούς και τριγλώχινας

Ακτινοθεραπεία Ακτινοβιολογία

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ. Πτυχιακή Εργασία

Best of Uro-oncology Kidney Cancer 2016

FACE CARES BASIC CARES

ΚΑΘΟΡΙΣΜΟΣ ΠΑΡΑΓΟΝΤΩΝ ΠΟΥ ΕΠΗΡΕΑΖΟΥΝ ΤΗΝ ΠΑΡΑΓΟΜΕΝΗ ΙΣΧΥ ΣΕ Φ/Β ΠΑΡΚΟ 80KWp

Πρόοδοι στην Απεικόνιση με PET/CT Σε ποιές παθήσεις? Πότε?

ΒUDD-CHIARI SYNDROME (SBC) Νικόλαος Χ. Γραμματικός Γαστρεντερολόγος, Επιμελητής Β ΕΣΥ Β Προπ. Παθολογική Κλινική, ΓΠΝΘ Ιπποκράτειο

Νευροφυσιολογία και Αισθήσεις

Aluminum Electrolytic Capacitors

Supplementary Table S1. Sensitivity to JQ1 of a Collection of Cancer Cell Lines

Parotid gland Surgery: A two years audit in a Tertiary Hospital.

masterclass program in rare cancers focus on sarcomas organized by january royal olympic hotel athens greece under the auspices of

Graded Refractive-Index

Supplemental Table S1. Tumor specific networks are enriched with somatically mutated genes (taken from the database COSMIC)

ΣΤΟΝ ΚΑΡΚΙΝΟ. Πάρις Α. Κοσμίδης Παθολόγος Ογκολόγος Νοσοκομείο «ΥΓΕΙΑ»

Resurvey of Possible Seismic Fissures in the Old-Edo River in Tokyo

GDF-15 is a predictor of cardiovascular events in patients presenting with suspicion of ACS

TSH 37.4%~91.8% 46.5%~94.1% 8 3. [DOI] /j.issn

Προενταξιακός ασθενής - Επιλογή μεθόδου κάθαρσης

Hits (L AND R) MIDDLE Right Side Hits (L AND R) MIDDLE Left Side

Hits (L AND R) MIDDLE Right Side Hits (L AND R) MIDDLE Left Side

Chinese Clinical Oncology Nov Vol. 19 No. 11 B MALT

HIV HIV HIV HIV AIDS 3 :.1 /-,**1 +332

TGFp FSH INH INH

Παράγοντες κινδύνου κακώσεων υψηλού επιπέδου στο γυναικείο ποδόσφαιρο. Ιντζεγιάννη Κωνσταντίνα, Κωφοτόλης Νίκος Κέλλης Ελευθέριος

Νευροενδοκρινείς όγκοι. Συνδυασμοί θεραπειών: Κατευθυντήριες οδηγίες, νεότερες εξελίξεις

Hits (L AND R) MIDDLE Right Side Hits (L AND R) MIDDLE Left Side. Hits (L AND R) BOTTOM Right Side Hits (L AND R) BOTTOM Left Sid 45

Επιλογή ασθενών και παρακολούθηση τους

ΑΚΤΙΝΟΘΕΡΑΠΕΥΤΙΚΗ ΠΡΟΣΕΓΓΙΣΗ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΠΡΟΣΤΑΤΟΥ - ΠΟΤΕ?

ΔΙΑΓΝΩΣΤΙΚΗ ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΠΡΟΣΕΓΓΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΚΑΡΚΙΝΟ

TNF TNF Karnofsky [6] /L /L 90 g/l 1 >3. rmhtnf. rmhtnf. rmhtnf. rmhtnf [3-5] rmhtnf 400 U/m 2 CR.

Section 8.3 Trigonometric Equations

C.S. 430 Assignment 6, Sample Solutions

Η ΘΕΣΗ ΤΗΣ ΛΕΜΦΑ ΕΝΕΚΤΟΜΗΣ ΣΤΟ ΚΑΡΚΙΝΟ ΤΟΥ ΝΕΦΡΟΥ

ΥΤ παιδιών στην Ελλάδα

ΘΕΡΑΠΕΙΑ ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΠΝΕΥΜΟΝΑ. Σοφία Παπακάτσικα ειδικευόμενη Ογκολογίας

Πτυχιακή Εργασία Η ΠΟΙΟΤΗΤΑ ΖΩΗΣ ΤΩΝ ΑΣΘΕΝΩΝ ΜΕ ΣΤΗΘΑΓΧΗ

SHOOT THE EXPERT: ΝΕT παγκρέατος

Transcript:

1 General Features of Brain Tumors 1. Total Registered Number 1) Number of Primary and Metastatic Brain Tumors 1984 1985 1986 1987 1988 1989 1990 1991 primary 3,491 3,593 3,530 3,673 4,108 4,400 3,998 4,302 metastatic 730 716 730 750 851 955 881 926 4,221 4,309 4,260 4,423 4,959 5,355 4,879 5,228 1992 1993 1994 1995 1996 1997 1998 1999 primary 4,446 4,402 4,737 4,609 4,646 3,458 3,714 3,767 metastatic 853 902 878 925 982 757 881 928 5,299 5,304 5,615 5,534 5,628 4,215 4,595 4,695 2000 primary 3,407 68,281 metastatic 918 14,563 4,325 82,844 2) Age Distribution of Primary Brain Tumors (1984-2000) age male (%) female (%) (%) 0 172 (0.6) 183 (0.5) 355 (0.5) 1 187 (0.6) 133 (0.4) 320 (0.5) 2 146 (0.5) 119 (0.3) 265 (0.4) 3 142 (0.5) 123 (0.3) 265 (0.4) 4 170 (0.6) 132 (0.4) 302 (0.5) 05-09 925 (3.1) 732 (2.0) 1,657 (2.5) 10-14 1,213 (4.0) 794 (2.1) 2,007 (3.0) 15-19 1,230 (4.1) 980 (2.6) 2,210 (3.3) 20-24 1,248 (4.1) 1,395 (3.7) 2,643 (3.9) 25-29 1,312 (4.3) 1,572 (4.2) 2,884 (4.3) 30-34 1,460 (4.8) 1,620 (4.3) 3,080 (4.6) 35-39 1,942 (6.4) 2,003 (5.4) 3,945 (5.8) 40-44 2,261 (7.5) 2,669 (7.1) 4,930 (7.3) 45-49 2,600 (8.6) 3,528 (9.4) 6,128 (9.0) 50-54 2,952 (9.7) 4,011 (10.7) 6,963 (10.3) 55-59 3,156 (10.4) 4,169 (11.1) 7,325 (10.8) 60-64 3,084 (10.2) 4,134 (11.0) 7,218 (10.7) 65-69 2,741 (9.0) 3,999 (10.7) 6,740 (10.0) 70-74 1,919 (6.3) 2,947 (7.9) 4,866 (7.2) 75-79 1,036 (3.4) 1,561 (4.2) 2,597 (3.8) 80-84 333 (1.1) 527 (1.4) 860 (1.3) 85-90 76 (0.3) 108 (0.3) 184 (0.3) 90-94 9 (0.0) 8 (0.0) 17 (0.0) 95-00 - ( - ) 3 (0.0) 3 (0.0) 30,314 (100.0) 37,450 (100.0) 67,764 (100.0) 242 275 517

2 3) Annual Trend of Frequency of Various Brain Tumors year meningioma 1984 23.7 8.9 17.2 27.7 12.8 9.3 1985 23.3 9.2 16.8 28.7 13.7 9.0 1986 25.6 9.7 16.4 27.3 13.1 8.4 1987 25.3 9.5 16.0 27.4 13.6 7.8 1988 25.3 9.7 15.7 27.9 13.4 9.1 1989 25.9 9.6 16.1 27.1 13.4 9.0 1990 26.6 10.9 16.8 25.4 11.8 9.0 1991 24.8 10.6 17.1 25.4 12.3 8.8 1992 24.6 11.7 18.4 23.6 11.0 8.5 1993 25.1 10.9 18.4 23.7 10.7 8.7 1994 27.0 9.9 19.5 22.8 10.0 8.9 1995 25.9 10.0 18.7 23.5 10.7 8.9 1996 27.5 9.6 18.0 22.7 10.1 8.4 1997 26.8 9.8 18.8 23.9 9.7 9.5 1998 27.8 9.0 18.7 23.4 9.7 8.8 1999 25.6 11.5 18.1 23.7 9.2 9.8 2000 26.3 10.6 18.9 24.1 9.3 9.7 * cases included for number ** malignant cases included % in all primary brain tumors in each year * pituitary neurinoma all glioma astrocytoma ** glioblastoma adenoma

3 4) Annual Trend of Frequency of Brain Tumors by Age Distribution * (1984-2000) all primary brain tumor meningioma ** neurinoma **(schwannoma) astrocytoma ** glioblastoma 1984-88 1989-92 1993-96 1997-00 1984-88 1989-92 1993-96 1997-00 1984-88 1989-92 1993-96 1997-00 1984-88 1989-92 1993-96 1997-00 1984-88 1989-92 1993-96 1997-00 0-4 500 380 355 272 6 9 4 3 1 1 1 1 119 88 78 54 13 11 7 14 5-9 564 459 390 244 11 9 8 3 5 4-2 129 129 100 55 19 24 11 14 10-14 718 490 456 343 16 13 11 9 10 4 8 4 164 104 102 59 20 23 13 14 15-19 635 592 579 404 22 15 24 7 16 20 20 23 118 86 91 62 21 28 18 18 20-24 707 641 771 524 42 27 38 31 36 45 43 33 90 100 109 68 25 32 25 22 25-29 793 661 831 599 54 58 45 54 44 69 69 54 126 110 130 92 42 25 31 28 30-34 948 752 743 637 126 73 89 63 97 74 66 72 169 132 112 112 53 40 37 33 35-39 1,401 935 876 733 237 171 155 128 133 97 110 95 251 155 115 103 79 55 58 43 40-44 1,375 1,473 1,254 828 359 301 289 200 164 210 156 104 189 205 156 96 88 93 79 53 45-49 1,537 1,508 1,848 1,235 452 428 562 337 203 221 248 147 169 164 168 118 106 99 125 78 50-54 1,870 1,700 1,832 1,561 586 525 598 516 266 263 249 238 190 162 155 89 177 137 142 132 55-59 2,024 1,859 1,928 1,514 655 641 654 512 299 251 260 188 210 153 135 100 212 198 190 152 60-64 1,753 1,885 1,987 1,593 646 631 721 526 195 259 245 188 161 166 132 95 232 234 222 199 65-69 1,454 1,654 2,040 1,592 534 662 797 614 152 173 208 146 147 123 135 96 194 192 277 199 70-74 1,164 1,088 1,391 1,223 500 463 533 483 66 86 125 109 123 97 97 72 189 167 202 186 75-59 614 647 694 642 270 272 295 255 34 41 40 40 59 74 49 55 87 98 105 109 80-84 143 218 274 225 59 93 107 93 5 8 14 10 18 17 23 22 28 34 44 40 85-00 29 42 56 77 12 14 26 30 1 3 2 1 1 2 6 2 7 6 8 10 18,229 16,984 18,305 14,246 4,587 4,405 4,956 3,864 1,727 1,829 1,864 1,455 2,433 2,067 1,893 1,350 1,592 1,496 1,594 1,344 166 162 89 100 45 45 20 23 12 10 4 15 19 13 16 9 12 15 12 10 * cases included ** malignant cases included

4 2. Resident Area & Birth Place: All Primary Brain Tumors prefecture residence birthplace prefecture residence birthplace 01 Hokkaido 2,232 964 27 Osaka 6,477 714 02 Aomori 820 493 28 Hyogo 3,200 880 03 Iwate 645 425 29 Nara 1,024 74 04 Miyagi 1,143 550 30 Wakayama 1,011 286 05 Akita 445 349 31 Tottori 215 144 06 Yamagata 858 673 32 Shimane 652 267 07 Fukusima 1,047 613 33 Okayama 973 500 08 Ibaraki 1,452 316 34 Hiroshima 1,702 484 09 Tochigi 1,050 218 35 Yamaguchi 1,359 557 10 Gunma 1,106 465 36 Tokushima 366 258 11 Saitama 2,318 564 37 Kagawa 426 164 12 Chiba 1,420 211 38 Ehime 1,127 290 13 Tokyo 5,764 1,235 39 Kochi 385 120 14 Kanagawa 3,836 597 40 Fukuoka 2,739 430 15 Niigata 2,133 1,309 41 Saga 676 353 16 Toyama 790 551 42 Nagasaki 544 168 17 Ishikawa 1,238 461 43 Kumamoto 1,205 299 18 Fukui 943 404 44 Oita 1,185 300 19 Yamanashi 650 227 45 Miyazaki 1,128 367 20 Nagano 762 177 46 Kagoshima 684 297 21 Gifu 1,447 481 47 Okinawa 129 108 22 Shizuoka 1,538 487 52 foreign country 0 1 23 Aichi 2,455 376 99 1,192 48,203 24 Mie 1,138 317 25 Shiga 984 276 26 Kyoto 1,668 278 68,281 68,281

5 3. Frequency of Primary Brain Tumors Frequency of Tumors by Histology (1984-2000) histology number % ganglioglioma 265 0.4 anaplastic gangliglioma 47 0.1 sympathicoblastoma 24 0.0 neuroblastoma 97 0.1 medulloepithelioma 13 0.0 neuroepithelioma 20 0.0 polar spongioblastoma 52 0.1 astrocytoma 4,693 7.1 anaplastic astrocytoma 3,107 4.7 oligodendroglioma 610 0.9 anaplastic oligodendroglioma 162 0.2 mixed glioma 335 0.5 ependymoma 545 0.8 anaplastic ependymoma 165 0.2 plexus papilloma 180 0.3 malignant plexus papilloma 30 0.0 glioblastoma 6,075 9.1 medulloblastoma 719 1.1 neurinoma 6,887 10.4 von Recklinghausen's disease 180 0.3 malignant neurinoma(schwannoma) 29 0.0 meningioma 17,575 26.4 malignant meningioma 370 0.6 hemangioblastoma 1,131 1.7 hemangiopericytoma 155 0.2 germinoma 1,258 1.9 pineocytoma 121 0.2 pineoblastoma 78 0.1 pituitary adenoma * 2,537 3.8 non-functioning pituitary adenoma 4,335 6.5 HGH producing pituitary adenoma 2,051 3.1 PRL producing pituitary adenoma 2,363 3.6 ACTH producing pituitary adenoma 549 0.8 other functioning pituitary adenoma 205 0.3 malignant pituitary adenoma 16 0.0 craniopharyngioma 2,353 3.5 glioma of pituitary region 12 0.0 teratoma 116 0.2 malignant teratoma 112 0.2 choriocarcinoma 55 0.1 embryonal carcinoma 65 0.1 yolk sac tumor 59 0.1 other germ cell tumor 150 0.2 dermoid 150 0.2 epidermoid 838 1.3 chordoma 302 0.5 malignant chordoma 8 0.0 tumor of bone and cartilage 284 0.4 lipoma 134 0.2 malignant lymphoma 2,045 3.1 other sarcoma 143 0.2 primary malignant melanoma 51 0.1 glioma ** 484 0.7 multiple 47 0.1 others 1,902 2.9 unclassified tumor 202 0.3 66,491 100.0 unkown 1,790 * number of the pituitary adenoma by classic classification ** not verified in detail

6 4. Age Distribution of Various Brain Tumors (1984-2000) sympathicoblastoma ganglioglioma malignant gangliglioma age and paraganglioma neuroblastoma medulloepithelioma m f (%) m f (%) m f (%) m f (%) m f (%) 0 5 2 7 (2.7) - - - (-) - - - (-) 4 2 6 (6.3) - - - (-) 1 4 2 6 (2.3) 1 1 2 (4.3) 1-1 (4.2) 1 2 3 (3.2) 1-1 (7.7) 2-4 4 (1.5) - - - (-) - - - (-) - - - (-) - - - (-) 3 - - - (-) - - - (-) - - - (-) 1 1 2 (2.1) 1-1 (7.7) 4 2 1 3 (1.1) 1 2 3 (6.4) - - - (-) 2 2 4 (4.2) - - - (-) 5-9 12 11 23 (8.8) 2 2 4 (8.5) - - - (-) 3 8 11 (11.6) 1-1 (7.7) 10-14 23 6 29 (11.0) 1-1 (2.1) - - - (-) 3 1 4 (4.2) 1 1 2 (15.4) 15-19 17 21 38 (14.5) 2 2 4 (8.5) - - - (-) 2 3 5 (5.3) - 1 1 (7.7) 20-24 20 12 32 (12.2) 1 2 3 (6.4) - 1 1 (4.2) 1-1 (1.1) - 1 1 (7.7) 25-29 16 13 29 (11.0) - - - (-) - - - (-) 3 4 7 (7.4) - - - (-) 30-34 10 8 18 (6.8) 2 1 3 (6.4) 1-1 (4.2) 3-3 (3.2) - - - (-) 35-39 5 7 12 (4.6) 2 1 3 (6.4) - - - (-) 5 1 6 (6.3) 1-1 (7.7) 40-44 5 5 10 (3.8) 1-1 (2.1) 2 2 4 (16.7) 5 1 6 (6.3) 1-1 (7.7) 45-49 8 7 15 (5.7) 2 5 7 (14.9) 3 1 4 (16.7) 4 3 7 (7.4) - 1 1 (7.7) 50-54 4 3 7 (2.7) 1 1 2 (4.6) - 5 5 (20.8) 5 1 6 (6.3) 1-1 (7.7) 55-59 7 4 11 (4.2) 3 1 4 (8.5) 2-2 (8.3) 5 4 9 (9.5) 1-1 (7.7) 60-64 6-6 (2.3) 1 2 3 (6.4) - 4 4 (16.7) 4 4 8 (8.4) 1-1 (7.7) 65-69 3 4 7 (2.7) 1 1 2 (4.3) - 1 1 (4.2) 3 2 5 (5.3) - - - (-) 70-74 4-4 (1.5) 2 1 3 (6.4) - - - (-) - - - (-) - - - (-) 75-79 1-1 (0.4) 1 1 2 (4.3) - 1 1 (4.2) 1-1 (1.1) - - - (-) 80-84 1-1 (0.4) - - - (-) - - - (-) - 1 1 (1.1) - - - (-) 85-90 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 153 110 263 (100.0) 24 23 47 (100.0) 9 15 24 (100.0) 55 40 95 (100.0) 9 4 13 (100.0) 2 2 2 2 m:male, f:female age neuroepithelionma polar spongioblastoma astrocytoma anaplastic astrocytoma m f (%) m f (%) m f (%) m f (%) 0 - - - (-) 1-1 (1.9) 19 25 44 (0.9) 7 8 15 (0.5) 1 - - - (-) - - - (-) 28 29 57 (1.2) 7 6 13 (0.4) 2 - - - (-) - 3 3 (5.8) 31 23 54 (1.2) 6 7 13 (0.4) 3 - - - (-) 2 1 3 (5.8) 32 29 61 (1.3) 2 4 6 (0.2) 4 - - - (-) 1 2 3 (5.8) 37 31 68 (1.5) 2 6 8 (0.3) 5-9 1 1 2 (10.0) 2 8 10 (19.2) 149 156 305 (6.6) 55 53 108 (3.5) 10-14 1-1 (5.0) 2 5 7 (13.5) 173 155 328 (7.0) 60 41 101 (3.3) 15-19 - - - (-) 3 5 8 (15.4) 144 135 279 (6.0) 45 33 78 (2.5) 20-24 2 1 3 (15.0) 1-1 (1.9) 146 131 277 (5.9) 50 40 90 (2.9) 25-29 1 1 2 (10.0) 1-1 (1.9) 166 152 318 (6.8) 88 52 140 (4.6) 30-34 - - - (-) 2 1 3 (5.8) 197 151 348 (7.5) 97 80 177 (5.8) 35-39 - - - (-) 2 2 4 (7.7) 246 154 400 (8.6) 136 88 224 (7.3) 40-44 3-3 (15.0) - - - (-) 237 182 419 (9.0) 129 98 227 (7.4) 45-49 2-2 (10.0) 1-1 (1.9) 189 162 351 (7.5) 152 116 268 (8.7) 50-54 2-2 (10.0) 1-1 (1.9) 200 116 316 (6.8) 149 131 280 (9.1) 55-59 - 2 2 (10.0) 2-2 (3.9) 146 146 292 (6.3) 178 128 306 (9.9) 60-64 - 1 1 (5.0) 1 2 3 (5.8) 128 109 237 (5.1) 180 137 317 (10.3) 65-69 1-1 (5.0) - - - (-) 114 110 224 (4.8) 158 119 277 (9.0) 70-74 - - - (-) - 1 1 (1.9) 70 80 150 (3.2) 121 118 239 (7.8) 75-79 1-1 (5.0) - - - (-) 55 49 104 (2.2) 76 57 133 (4.3) 80-84 - - - (-) - - - (-) 12 17 29 (0.6) 27 24 51 (1.7) 85-90 - - - (-) - - - (-) 3 1 4 (0.1) 6 1 7 (0.2) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) 14 6 20 (100.0) 22 30 52 (100.0) 2,522 2,143 4,665 (100.0) 1,731 1,347 3,078 (100.0) 16 12 28 18 11 29

7 anaplastic oligodendroglioma age oligodendroglioma mixed glioma ependymoma m f (%) m f (%) m f (%) m f (%) 0 1-1 (0.2) - - - (-) - 1 1 (0.3) 3 10 13 (2.4) 1 - - - (-) - - - (-) - - - (-) 22 12 34 (6.3) 2 1 1 2 (0.3) - - - (-) 2 2 4 (1.2) 17 12 29 (5.4) 3 1-1 (0.2) - - - (-) 1 3 4 (1.2) 15 10 25 (4.6) 4-1 1 (0.2) - - - (-) - 1 1 (0.3) 12 4 16 (3.0) 5-9 5 6 11 (1.8) 1-1 (0.6) 7 4 11 (3.3) 39 32 71 (13.2) 10-14 16 7 23 (3.8) 2-2 (1.2) 5 2 7 (2.1) 21 16 37 (6.9) 15-19 11 13 24 (4.0) 1 1 2 (1.2) 6-6 (1.8) 18 22 40 (7.4) 20-24 13 12 25 (4.1) 5 1 6 (3.7) 6 8 14 (4.2) 18 20 38 (7.1) 25-29 22 22 44 (7.3) 1 2 3 (1.9) 12 4 16 (4.8) 13 12 25 (4.6) 30-34 31 22 53 (8.8) 6 2 8 (5.0) 19 8 27 (8.1) 10 5 15 (2.8) 35-39 35 21 56 (9.2) 8 4 12 (7.5) 19 14 33 (9.9) 20 13 33 (6.1) 40-44 45 37 82 (13.5) 9 7 16 (9.9) 28 21 49 (14.7) 12 22 34 (6.3) 45-49 37 34 71 (11.7) 12 10 22 (13.7) 32 10 42 (12.6) 11 18 29 (5.4) 50-54 35 40 75 (12.4) 13 6 19 (11.8) 17 17 34 (10.2) 14 15 29 (5.4) 55-59 16 28 44 (7.3) 13 5 18 (11.2) 29 12 41 (12.3) 11 9 20 (3.7) 60-64 21 20 41 (6.8) 16 7 23 (14.3) 9 9 18 (5.4) 10 17 27 (5.0) 65-69 10 17 27 (4.5) 8 5 13 (8.1) 3 12 15 (4.5) 9 7 16 (3.0) 70-74 8 10 18 (3.0) 9 5 14 (8.7) 4 2 6 (1.8) 2 1 3 (0.6) 75-79 4 3 7 (1.2) 2-2 (1.2) 2 1 3 (0.9) 3 2 5 (0.9) 80-84 - - - (-) - - - (-) 1 1 2 (0.6) - - - (-) 85-90 - - - (-) - - - (-) - - - (-) - - - (-) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) 312 294 606 (100.0) 106 55 161 (100.0) 202 132 334 (100.0) 280 259 539 (100.0) 1 3 4 1 1 1 1 4 2 6 anaplastic malignant plexus plexus papilloma age ependymoma papilloma glioblastoma m f (%) m f (%) m f (%) m f (%) 0 7 13 20 (12.3) 27 13 40 (22.4) 4 2 6 (20.0) 3 6 9 (0.2) 1 7 9 16 (9.8) 6 4 10 (5.6) 4-4 (13.3) 1 3 4 (0.1) 2 7 6 13 (8.0) 4 2 6 (3.4) 2-2 (6.7) 7 2 9 (0.2) 3 1 5 6 (3.7) 7 3 10 (5.6) 1 2 3 (10.0) 8 4 12 (0.2) 4 4 5 9 (5.5) 1-1 (0.6) - - - (-) 9 2 11 (0.2) 5-9 8 7 15 (9.2) 7 2 9 (5.0) - - - (-) 39 29 68 (1.1) 10-14 7 8 15 (9.2) 2-2 (1.1) 1 1 2 (6.7) 37 33 70 (1.2) 15-19 - 5 5 (3.1) 2 1 3 (1.7) - - - (-) 55 30 85 (1.4) 20-24 4 2 6 (3.7) 7 7 14 (7.8) - 1 1 (3.3) 71 33 104 (1.7) 25-29 0 5 5 (3.1) 5 3 8 (4.5) - - - (-) 78 48 126 (2.1) 30-34 1 4 5 (3.1) 5 5 10 (5.6) 1 3 4 (13.3) 93 70 163 (2.7) 35-39 5 2 7 (4.3) 4 3 7 (3.9) - - - (-) 153 82 235 (3.9) 40-44 3 2 5 (3.1) 4 5 9 (5.0) - - - (-) 185 128 313 (5.2) 45-49 7 2 9 (5.5) 2 8 10 (5.6) - 1 1 (3.3) 241 167 408 (6.8) 50-54 2 3 5 (3.1) 1 4 5 (2.8) 1 2 3 (10.0) 385 203 588 (9.8) 55-59 2 2 4 (2.5) 7 9 16 (8.9) - 2 2 (6.7) 464 288 752 (12.5) 60-64 5 3 8 (4.9) 1 5 6 (3.4) 1-1 (3.3) 549 338 887 (14.7) 65-69 3 3 6 (3.7) 3 2 5 (2.8) - - - (-) 477 385 862 (14.3) 70-74 1 2 3 (1.8) 3 2 5 (2.8) 1-1 (3.3) 418 326 744 (12.4) 75-79 - 1 1 (0.6) - 1 1 (0.6) - - - (-) 210 189 399 (6.6) 80-84 - - - (-) 1-1 (0.6) - - - (-) 76 70 146 (2.4) 85-90 - - - (-) - 1 1 (0.6) - - - (-) 15 14 29 (0.5) 90-94 - - - (-) - - - (-) - - - (-) 2-2 (0.0) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) 74 89 163 (100.0) 99 80 179 (100.0) 16 14 30 (100.0) 3,576 2,450 6,026 (100.0) 2 2 1 1 27 22 49

8 neurinoma malignant neurinoma medulloblastoma neurofibromatosis age (schwannoma) (schwannoma) m f (%) m f (%) m f (%) m f (%) 0 21 13 34 (4.8) - 3 3 (0.0) - 1 1 (0.6) - - - (-) 1 43 23 66 (9.4) - - - (-) 1 1 2 (1.1) - - - (-) 2 24 16 40 (5.7) - - - (-) - - - (-) - - - (-) 3 20 12 32 (4.5) - 1 1 (0.0) - - - (-) - - - (-) 4 24 25 49 (7.0) - - - (-) 1 1 2 (1.1) - - - (-) 5-9 155 76 231 (32.8) 2 9 11 (0.2) 4 7 11 (6.2) - - - (-) 10-14 83 58 141 (20.0) 9 16 25 (0.4) 7 10 17 (9.5) 1-1 (3.6) 15-19 25 19 44 (6.2) 35 44 79 (1.2) 15 10 25 (14.0) - - - (-) 20-24 12 11 23 (3.3) 68 89 157 (2.3) 9 13 22 (12.3) - - - (-) 25-29 10 8 18 (2.6) 113 122 235 (3.4) 6 9 15 (8.4) - 1 1 (3.6) 30-34 3 3 6 (0.9) 128 180 308 (4.5) 8 5 13 (7.3) - 1 1 (3.6) 35-39 2 5 7 (1.0) 215 217 432 (6.3) 5 6 11 (6.2) 2 1 3 (10.7) 40-44 2 3 5 (0.7) 304 329 633 (9.2) 5 3 8 (4.5) 1-1 (3.6) 45-49 3-3 (0.4) 362 453 815 (11.9) 6 10 16 (8.9) 2 2 4 (14.3) 50-54 2 1 3 (0.4) 425 589 1,014 (14.8) 6 8 14 (7.8) - 2 2 (7.1) 55-59 - - - (-) 437 557 994 (14.5) 5 3 8 (4.5) 2 2 4 (14.3) 60-64 - - - (-) 363 518 881 (12.9) 3 2 5 (2.8) 3 3 6 (21.4) 65-69 - - - (-) 282 396 678 (9.9) 1 2 3 (1.7) 1-1 (3.6) 70-74 - 2 2 (0.3) 133 252 385 (5.6) 1 3 4 (2.2) - 1 1 (3.6) 75-79 - - - (-) 45 108 153 (2.2) - 1 1 (0.6) 1 1 2 (7.1) 80-84 1-1 (0.1) 14 22 36 (0.5) - - - (-) - 1 1 (3.6) 85-90 - - - (-) 3 4 7 (0.1) 1-1 (0.6) - - - (-) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) 430 275 705 (100.0) 2,938 3,909 6,847 (100.0) 84 95 179 (100.0) 13 15 28 (100.0) 10 4 14 15 25 40 1 1 1 1 age meningioma malignant meningioma hemangioblastoma hemangiopericytoma m f (%) m f (%) m f (%) m f (%) 0 5 3 8 (0.1) - 1 1 (0.3) 2 1 3 (0.3) 1-1 (0.7) 1 2 2 4 (0.0) - - - (-) 1-1 (0.1) - - - (-) 2 3-3 (0.0) - - - (-) - - - (-) - - - (-) 3 1 2 3 (0.0) 1-1 (0.3) - - - (-) - - - (-) 4-1 1 (0.0) 1-1 (0.3) 1-1 (0.1) - - - (-) 5-9 16 12 28 (0.2) 2 1 3 (0.8) 1 2 3 (0.3) 2 1 3 (2.0) 10-14 28 19 47 (0.3) 2-2 (0.6) 6 11 17 (1.5) 1 1 2 (1.3) 15-19 34 30 64 (0.4) 2 2 4 (1.1) 25 23 48 (4.3) 4 3 7 (4.6) 20-24 64 68 132 (0.8) 5 1 6 (1.7) 33 33 66 (5.9) 6 5 11 (7.1) 25-29 95 109 204 (1.2) 3 4 7 (1.9) 47 36 83 (7.4) 10 5 15 (9.7) 30-34 124 218 342 (2.0) 4 5 9 (2.5) 43 47 90 (8.0) 6 4 10 (6.5) 35-39 200 475 675 (3.9) 7 9 16 (4.4) 61 39 100 (8.9) 4 4 8 (5.2) 40-44 304 820 1,124 (6.4) 13 12 25 (6.9) 56 50 106 (9.4) 6 4 10 (6.5) 45-49 430 1,318 1,748 (10.0) 12 19 31 (8.5) 62 59 121 (10.8) 13 10 23 (14.9) 50-54 541 1,653 2,194 (12.6) 14 17 31 (8.5) 70 54 124 (11.0) 5 7 12 (7.8) 55-59 620 1,806 2,426 (13.9) 15 21 36 (9.9) 58 51 109 (9.7) 9 7 16 (10.4) 60-64 659 1,819 2,478 (14.2) 21 25 46 (12.6) 54 40 94 (8.4) 6 3 9 (5.8) 65-69 669 1,890 2,559 (14.7) 22 26 48 (13.2) 40 36 76 (6.8) 6 9 15 (9.7) 70-74 494 1,440 1,934 (11.1) 18 27 45 (12.4) 29 29 58 (5.2) 1 3 4 (2.6) 75-79 289 771 1,060 (6.1) 13 19 32 (8.8) 13 7 20 (1.8) 2 4 6 (3.9) 80-84 90 247 337 (1.9) 7 8 15 (4.1) 1 3 4 (0.4) - 2 2 (1.3) 85-90 20 49 69 (0.4) 4-4 (1.1) 1 1 2 (0.2) - - - (-) 90-94 3 3 6 (0.0) 1-1 (0.3) - - - (-) - - - (-) 95-00 - 2 2 (0.0) - - - (-) - - - (-) - - - (-) 4,691 12,757 17,448 (100.0) 167 197 364 (100.0) 604 522 1,126 (100.0) 82 72 154 (100.0) 38 89 127 5 1 6 3 2 5 1 1

9 age germinoma pineocytoma pineoblastoma pituitary adenoma m f (%) m f (%) m f (%) m f (%) 0 2 1 3 (0.2) - 1 1 (0.8) 4 1 5 (6.5) - 1 1 (0.0) 1 2 1 3 (0.2) - - - (-) 5-5 (6.5) 1-1 (0.0) 2 1-1 (0.1) - - - (-) 2 1 3 (3.9) - - - (-) 3-1 1 (0.1) - - - (-) 3 1 4 (5.2) - - - (-) 4 1 1 2 (0.2) - - - (-) - - - (-) - - - (-) 5-9 55 40 95 (7.6) 1 2 3 (2.5) 4 2 6 (7.8) 1 1 2 (0.1) 10-14 261 96 357 (28.7) 6 1 7 (5.8) 4 4 8 (10.4) 8 14 22 (0.9) 15-19 282 57 339 (27.2) 9 2 11 (9.2) 4 1 5 (6.5) 22 46 68 (2.7) 20-24 199 21 220 (17.7) 5 7 12 (10.0) 4 2 6 (7.8) 35 111 146 (5.8) 25-29 86 16 102 (8.2) 5 3 8 (6.7) 3 1 4 (5.2) 44 99 143 (5.7) 30-34 37 10 47 (3.8) 4 4 8 (6.7) 4-4 (5.2) 55 96 151 (6.0) 35-39 22 4 26 (2.1) 5 5 10 (8.3) 1 5 6 (7.8) 94 106 200 (7.9) 40-44 14 4 18 (1.4) 5 5 10 (8.3) 2 2 4 (5.2) 120 125 245 (9.7) 45-49 9 7 16 (1.3) 6 4 10 (8.3) 2 3 5 (6.5) 126 165 291 (11.6) 50-54 2 1 3 (0.2) 6 10 16 (13.3) 1 2 3 (3.9) 137 149 286 (11.4) 55-59 4-4 (0.3) 3 3 6 (5.0) 1 2 3 (3.9) 138 134 272 (10.8) 60-64 4 2 6 (0.5) 8 3 11 (9.2) 1 1 2 (2.6) 124 126 250 (9.9) 65-69 1 1 2 (0.2) - 6 6 (5.0) - 1 1 (1.3) 101 119 220 (8.7) 70-74 - - - (-) - - - (-) - 1 1 (1.3) 65 71 136 (5.4) 75-79 1-1 (0.1) - - - (-) - - - (-) 29 40 69 (2.7) 80-84 - - - (-) 1-1 (0.8) - 2 2 (2.6) 6 7 13 (0.5) 85-90 - - - (-) - - - (-) - - - (-) 1 1 2 (0.1) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) 95- - - - (-) - - - (-) - - - (-) - - - (-) 983 263 1,246 (100.0) 64 56 120 (100.0) 45 32 77 (100.0) 1,107 1,411 2,518 (100.0) 9 3 12 1 1 1 1 7 12 19 *pituitary adenoma by classic classification age Non-functioning p. ad. HGH producing p. ad. PRL producing p. ad. ACTH producing p. ad. other functioning p. ad. m f (%) m f (%) m f (%) m f (%) m f (%) 0 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 1 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 2 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 3 1-1 (0.0) 1-1 (0.1) - - - (-) - - - (-) - - - (-) 4 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 5-9 - 1 1 (0.0) 2 2 4 (0.2) - 1 1 (0.0) 1 2 3 (0.6) 1-1 (0.5) 10-14 10 12 22 (0.5) 9 5 14 (0.7) 11 13 24 (1.0) 5 4 9 (1.7) 1-1 (0.5) 15-19 31 49 80 (1.9) 25 12 37 (1.8) 36 153 189 (8.1) 10 15 25 (4.6) 3 5 8 (3.9) 20-24 49 65 114 (2.7) 49 30 79 (3.9) 50 396 446 (19.0) 13 22 35 (6.4) 3 4 7 (3.4) 25-29 74 72 146 (3.4) 70 52 122 (6.0) 55 423 478 (20.4) 13 41 54 (9.9) 10 7 17 (8.3) 30-34 85 81 166 (3.9) 98 61 159 (7.8) 84 227 311 (13.3) 11 48 59 (10.8) 9 10 19 (9.3) 35-39 113 125 238 (5.5) 134 91 225 (11.1) 75 153 228 (9.7) 15 49 64 (11.7) 7 6 13 (6.4) 40-44 164 175 339 (7.9) 115 113 228 (11.2) 81 108 189 (8.1) 11 62 73 (13.4) 16 8 24 (11.8) 45-49 213 234 447 (10.4) 128 177 305 (15.0) 69 67 136 (5.8) 15 46 61 (11.2) 11 11 22 (10.8) 50-54 263 254 517 (12.0) 141 166 307 (15.1) 54 56 110 (4.7) 10 36 46 (8.4) 8 11 19 (9.3) 55-59 300 301 601 (14.0) 78 129 207 (10.2) 53 32 85 (3.6) 12 40 52 (9.5) 11 15 26 (12.8) 60-64 293 298 591 (13.8) 75 95 170 (8.4) 38 24 62 (2.7) 7 23 30 (5.5) 10 13 23 (11.3) 65-69 266 252 518 (12.1) 34 69 103 (5.1) 27 30 57 (2.4) 5 12 17 (3.1) 5 8 13 (6.4) 70-74 172 176 348 (8.1) 16 32 48 (2.4) 6 9 15 (0.6) 4 10 14 (2.6) 2 4 6 (2.9) 75-79 70 62 132 (3.1) 4 13 17 (0.8) 3 4 7 (0.3) - 3 3 (0.6) 1 2 3 (1.5) 80-84 18 14 32 (0.7) - 1 1 (0.1) 2 2 4 (0.2) - - - (-) 1 1 2 (1.0) 85-90 3 1 4 (0.1) 1-1 (0.1) - - - (-) - - - (-) - - - (-) 90-94 - 1 1 (0.0) - - - (-) - - - (-) - - - (-) - - - (-) 95- - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 2,125 2,173 4,298 (100.0) 980 1,048 2,028 (100.0) 644 1,698 2,342 (100.0) 132 413 545 (100.0) 99 105 204 (100.0) 16 21 37 7 16 23 10 11 21 1 3 4 1 1

10 age malignant pituitary glioma of pituitary region craniopharyngioma adenoma or neurohypophysis teratoma m f (%) m f (%) m f (%) m f (%) 0 - - - (-) 5 7 12 (0.5) - 1 1 (8.3) 5 2 7 (6.0) 1 - - - (-) 3 6 9 (0.4) - - - (-) 2-2 (1.7) 2 - - - (-) 5 8 13 (0.6) - - - (-) 2-2 (1.7) 3 - - - (-) 11 13 24 (1.0) - - - (-) 1-1 (0.9) 4 - - - (-) 23 15 38 (1.6) - - - (-) 4-4 (3.5) 5-9 1-1 (6.3) 106 64 170 (7.3) 1 1 2 (16.7) 17 4 21 (18.1) 10-14 - - - (-) 94 79 173 (7.4) - - - (-) 16 5 21 (18.1) 15-19 1-1 (6.3) 56 60 116 (5.0) 1 1 2 (16.7) 18 3 21 (18.1) 20-24 - - - (-) 59 68 127 (5.4) - - - (-) 6 2 8 (6.9) 25-29 - 1 1 (6.3) 45 68 113 (4.8) - - - (-) 3 1 4 (3.5) 30-34 1 1 2 (12.5) 65 61 126 (5.4) - - - (-) 2 2 4 (3.5) 35-39 1-1 (6.3) 95 66 161 (6.9) 1-1 (8.3) 4-4 (3.5) 40-44 - - - (-) 94 75 169 (7.2) - - - (-) 1 1 2 (1.7) 45-49 - - - (-) 113 95 208 (8.9) 1 1 2 (16.7) 1-1 (0.9) 50-54 1 3 4 (25.0) 102 85 187 (8.0) - 1 1 (8.3) 2 1 3 (2.6) 55-59 1-1 (6.3) 115 105 220 (9.4) 2-2 (16.7) - 2 2 (1.7) 60-64 1 1 2 (12.5) 77 93 170 (7.3) - - - (-) 1 3 4 (3.5) 65-69 2-2 (12.5) 66 100 166 (7.1) 1-1 (8.3) 1 2 3 (2.6) 70-74 - 1 1 (6.3) 28 60 88 (3.8) - - - (-) - 1 1 (0.9) 75-79 - - - (-) 13 23 36 (1.5) - - - (-) - - - (-) 80-84 - - - (-) 5 7 12 (0.5) - - - (-) 1-1 (0.9) 85-90 - - - (-) - 2 2 (0.1) - - - (-) - - - (-) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) 9 7 16 (100.0) 1,180 1,160 2,340 (100.0) 7 5 12 (100.0) 87 29 116 (100.0) 9 4 13 age malignant teratoma choriocarcinoma embryonal carcinoma yolk sac tumor other germ cell tumor m f (%) m f (%) m f (%) m f (%) m f (%) 0 4 3 7 (6.4) - - - (-) - - - (-) - 2 2 (3.5) - 2 2 (1.3) 1 - - - (-) - - - (-) - 1 1 (1.6) - - - (-) - - - (-) 2 2-2 (1.8) - - - (-) 1-1 (1.6) - - - (-) 1-1 (0.7) 3 2-2 (1.8) - - - (-) - 1 1 (1.6) 1-1 (1.7) - - - (-) 4 4-4 (3.6) 1 1 2 (3.6) - - - (-) - - - (-) 1-1 (0.7) 5-9 18 13 31 (28.2) 8 1 9 (16.4) 3 4 7 (10.9) 5 1 6 (10.3) 13 10 23 (15.4) 10-14 22 4 26 (23.6) 13 9 22 (40.0) 17 4 21 (32.8) 13 4 17 (29.3) 33 12 45 (30.2) 15-19 15 3 18 (16.4) 9 3 12 (21.8) 15-15 (23.4) 15 2 17 (29.3) 33 5 38 (25.5) 20-24 11-11 (10.0) 4 1 5 (9.1) 10-10 (15.6) 8-8 (13.8) 17 5 22 (14.8) 25-29 3-3 (2.7) - - - (-) 3-3 (4.7) - 1 1 (1.7) 4 2 6 (4.0) 30-34 - - - (-) 1 1 2 (3.6) 1-1 (1.6) 2 1 3 (5.2) - 2 2 (1.3) 35-39 1-1 (0.9) - - - (-) - - - (-) 1-1 (1.7) 1-1 (0.7) 40-44 2-2 (1.8) - - - (-) 1-1 (1.6) - - - (-) 1 1 2 (1.3) 45-49 1-1 (0.9) - - - (-) - - - (0) 1-1 (1.7) 2-2 (1.3) 50-54 1-1 (0.9) 1 1 2 (3.6) 1-1 (1.6) - - - (-) 1-1 (0.7) 55-59 - 1 1 (0.9) 1-1 (1.8) - - - (-) - - - (-) 1 2 3 (2.0) 60-64 - - - (-) - - - (-) 1-1 (1.6) - - - (-) - - - (-) 65-69 - - - (-) - - - (-) - 1 1 (1.6) 1-1 (1.7) - - - (-) 70-74 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 75-79 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 80-84 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 85-90 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 86 24 110 (100.0) 38 17 55 (100.0) 53 11 64 (100.0) 47 11 58 (100.0) 108 41 149 (100.0) 1 1 2 1 1 1 1 1 1

11 age dermoid epidermoid chordoma malignant chordoma tumor of bone and cartilage m f (%) m f (%) m f (%) m f (%) m f (%) 0 5 6 11 (7.4) 3 3 6 (0.7) - 1 1 (0.3) - - - (-) - 4 4 (1.4) 1 4 4 8 (5.4) - 4 4 (0.5) - - - (-) - - - (-) 3-3 (1.1) 2 2 2 4 (2.7) - 2 2 (0.2) - 1 1 (0.3) - - - (-) 1 3 4 (1.4) 3-1 1 (0.7) - 2 2 (0.2) - - - (-) - - - (-) - 3 3 (1.1) 4 1-1 (0.7) 2 1 3 (0.4) - - - (-) - - - (-) 2-2 (0.7) 5-9 5-5 (3.4) 4 4 8 (1.0) 4 1 5 (1.7) - - - (-) 10 14 24 (8.5) 10-14 3 5 8 (5.4) 4 7 11 (1.3) 4 3 7 (2.3) - - - (-) 16 8 24 (8.5) 15-19 3 6 9 (6.1) 12 8 20 (2.4) 11 6 17 (5.6) 1-1 (12.5) 15 10 25 (8.8) 20-24 5 6 11 (7.4) 14 9 23 (2.8) 4 9 13 (4.3) - - - (-) 6 19 25 (8.8) 25-29 4 4 8 (5.4) 31 31 62 (7.4) 11 9 20 (6.6) 1-1 (12.5) 7 8 15 (5.3) 30-34 7 4 11 (7.4) 25 27 52 (6.2) 8 12 20 (6.6) - - - (-) 8 13 21 (7.4) 35-39 3 6 9 (6.1) 42 58 100 (12.0) 10 10 20 (6.6) - 1 1 (12.5) 7 15 22 (7.8) 40-44 4 3 7 (4.7) 40 59 99 (11.9) 11 8 19 (6.3) 1-1 (12.5) 10 3 13 (4.6) 45-49 6 5 11 (7.4) 45 69 114 (13.7) 11 14 25 (8.3) - - - (-) 4 18 22 (7.8) 50-54 9 5 14 (9.5) 38 60 98 (11.7) 16 18 34 (11.3) 1-1 (12.5) 4 15 19 (6.7) 55-59 7 3 10 (6.8) 47 40 87 (10.4) 17 15 32 (10.6) - - - (-) 7 10 17 (6.0) 60-64 5 4 9 (6.1) 31 37 68 (8.1) 11 20 31 (10.3) - - - (-) 3 13 16 (5.6) 65-69 1 3 4 (2.7) 18 27 45 (5.4) 14 20 34 (11.3) 2 1 3 (37.5) 4 10 14 (4.9) 70-74 - 4 4 (2.7) 7 11 18 (2.2) 5 9 14 (4.6) - - - (-) 1 7 8 (2.8) 75-79 1 2 3 (2.0) 4 7 11 (1.3) 4 2 6 (2.0) - - - (-) 1 1 2 (0.7) 80-84 - - - (-) 1 1 2 (0.2) - 2 2 (0.7) - - - (-) - 1 1 (0.4) 85-90 - - - (-) - - - (-) - 1 1 (0.3) - - - (-) - - - (-) 90-94 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 75 73 148 (100.0) 368 467 835 (100.0) 141 161 302 (100.0) 6 2 8 (100.0) 109 175 284 (100.0) 2 2 1 2 3 primary malignant lipoma malignant lymphoma other sarcoma age melanoma glioma * m f (%) m f (%) m f (%) m f (%) m f (%) 0 3 5 8 (6.0) 1-1 (0.1) 1 1 2 (1.4) - - - (-) 3 2 5 (1.0) 1 1 1 2 (1.5) - - - (-) 1-1 (0.7) - - - (-) 5 4 9 (1.9) 2 - - - (-) 1-1 (0.1) - 2 2 (1.4) - - - (-) 5 2 7 (1.5) 3 1-1 (0.8) - 1 1 (0.1) 1-1 (0.7) - - - (-) 6 4 10 (2.1) 4 1-1 (0.8) 1 1 2 (0.1) 2-2 (1.4) - - - (-) 7 14 21 (4.4) 5-9 6 2 8 (6.0) 3 1 4 (0.2) 5 4 9 (6.4) 1-1 (2.0) 39 54 93 (19.4) 10-14 5 3 8 (6.0) 7 1 8 (0.4) 7 3 10 (7.1) 1-1 (2.0) 31 19 50 (10.4) 15-19 4 3 7 (5.3) 8 2 10 (0.5) 5 7 12 (8.5) - - - (-) 13 12 25 (5.2) 20-24 7 4 11 (8.3) 11 1 12 (0.6) 10 4 14 (9.9) 2 1 3 (5.9) 15 7 22 (4.6) 25-29 5 1 6 (4.5) 18 12 30 (1.5) 6 4 10 (7.1) 1 1 2 (3.9) 10 11 21 (4.4) 30-34 5 3 8 (6.0) 17 8 25 (1.2) 3 4 7 (5.0) 1-1 (2.0) 11 8 19 (4.0) 35-39 7 7 14 (10.5) 31 25 56 (2.8) 4 1 5 (3.6) - 2 2 (3.9) 10 10 20 (4.2) 40-44 7 4 11 (8.3) 50 37 87 (4.3) 4 4 8 (5.7) 6-6 (11.8) 9 20 29 (6.0) 45-49 4 3 7 (5.3) 69 39 108 (5.3) 2 4 6 (4.3) 4 3 7 (13.7) 13 10 23 (4.8) 50-54 3 6 9 (6.8) 94 83 177 (8.7) 8 4 12 (8.5) 4 3 7 (13.7) 12 10 22 (4.6) 55-59 5 2 7 (5.3) 154 103 257 (12.6) 2 4 6 (4.3) 6 1 7 (13.7) 12 4 16 (3.3) 60-64 3 3 6 (4.5) 216 128 344 (16.9) 5 3 8 (5.7) - 4 4 (7.8) 9 8 17 (3.5) 65-69 9 4 13 (9.8) 192 149 341 (16.8) 7 6 13 (9.2) 3 2 5 (9.8) 26 5 31 (6.5) 70-74 1 4 5 (3.8) 183 110 293 (14.4) 2 4 6 (4.3) 1-1 (2.0) 13 2 15 (3.1) 75-79 - 1 1 (0.8) 96 91 187 (9.2) 1 4 5 (3.6) 3 1 4 (7.8) 10 7 17 (3.5) 80-84 - - - (-) 25 44 69 (3.4) 1 1 2 (1.4) - - - (-) 4 3 7 (1.5) 85-90 - - - (-) 6 14 20 (1.0) - - - (-) - - - (-) - - - (-) 90-94 - - - (-) 1 1 2 (0.1) - - - (-) - - - (-) - 1 1 (0.2) 95-00 - - - (-) - - - (-) - - - (-) - - - (-) - - - (-) 77 56 133 (100.0) 1,184 851 2,035 (100.0) 77 64 141 (100.0) 33 18 51 (100.0) 263 217 480 (100.0) 1 1 8 2 10 2 2 3 1 4 * glioma, not verified in detail

12 age multiple others unclassified tumor m f (%) m f (%) m f (%) m f (%) m f (%) 0 - - - (-) 18 23 41 (2.2) 3 7 10 (5.0) 167 177 344 (0.5) 5 6 11 (0.6) 1 - - - (-) 19 8 27 (1.4) 2 3 5 (2.5) 178 126 304 (0.5) 9 7 16 (0.9) 2 - - - (-) 13 12 25 (1.3) - 1 1 (0.5) 140 112 252 (0.4) 6 7 13 (0.7) 3 - - - (-) 12 12 24 (1.3) 1 1 2 (1.0) 135 117 252 (0.4) 7 6 13 (0.7) 4-1 1 (2.2) 14 9 23 (1.2) 1 1 2 (1.0) 163 128 291 (0.4) 7 4 11 (0.6) 5-9 2 1 3 (6.5) 43 32 75 (4.0) 4 5 9 (4.5) 876 694 1,570 (2.4) 49 38 87 (4.9) 10-14 1 1 2 (4.4) 57 48 105 (5.6) 4 6 10 (5.0) 1,155 761 1,916 (2.9) 58 33 91 (5.2) 15-19 3-3 (6.5) 61 64 125 (6.6) 7 8 15 (7.5) 1,174 946 2,120 (3.2) 56 34 90 (5.1) 20-24 1 1 2 (4.4) 65 57 122 (6.5) 4 11 15 (7.5) 1,208 1,355 2,563 (3.9) 40 40 80 (4.5) 25-29 3-3 (6.5) 63 64 127 (6.7) 5 4 9 (4.5) 1,273 1,548 2,821 (4.3) 39 24 63 (3.6) 30-34 1-1 (2.2) 74 65 139 (7.4) 4 6 10 (5.0) 1,417 1,578 2,995 (4.5) 43 42 85 (4.8) 35-39 1 1 2 (4.4) 76 65 141 (7.5) 3 6 9 (4.5) 1,901 1,965 3,866 (5.9) 41 38 79 (4.5) 40-44 3 3 6 (13.0) 70 63 133 (7.0) 12 5 17 (8.5) 2,214 2,619 4,833 (7.3) 47 50 97 (5.5) 45-49 4 1 5 (10.9) 85 60 145 (7.7) 5 6 11 (5.5) 2,543 3,458 6,001 (9.1) 57 70 127 (7.2) 50-54 2 2 4 (8.7) 72 82 154 (8.2) 7 8 15 (7.5) 2,896 3,950 6,846 (10.4) 56 60 116 (6.6) 55-59 1 2 3 (6.5) 76 66 142 (7.5) 5 11 16 (8.0) 3,091 4,114 7,205 (10.9) 65 55 120 (6.8) 60-64 2 1 3 (6.5) 51 65 116 (6.1) 5 10 15 (7.5) 3,023 4,046 7,069 (10.7) 61 88 149 (8.4) 65-69 3 3 6 (13.0) 50 65 115 (6.1) 7 10 17 (8.5) 2,660 3,933 6,593 (10.0) 81 66 147 (8.3) 70-74 - 1 1 (2.2) 35 29 64 (3.4) - 3 3 (1.5) 1,860 2,854 4,714 (7.1) 59 93 152 (8.6) 75-79 - 1 1 (2.2) 16 18 34 (1.8) 2 6 8 (4.0) 978 1,504 2,482 (3.8) 58 57 115 (6.5) 80-84 - - - (-) 5 3 8 (0.4) 2-2 (1.0) 303 485 788 (1.2) 30 42 72 (4.1) 85-90 - - - (-) 1 1 2 (0.1) - - - (-) 65 91 156 (0.2) 11 17 28 (1.6) 90-94 - - - (-) 0 1 1 (0.1) - - - (-) 7 7 14 (0.0) 2 1 3 (0.2) 95-00 - - - (-) 0 1 1 (0.1) - - - (-) - 3 3 (0.0) - - - (-) 27 19 46 (100.0) 976 913 1,889 (100.0) 83 118 201 (100.0) 29,427 36,571 65,998 (100.0) 887 878 1,765 (100.0) 1 1 5 8 13 1 1 229 265 494 13 10 23

13 5. Age Distribution of Brain Tumors by Sites (1984-2000) 1) All Primary Brain Tumors : Supra or Infratentorial age supra- infrasupra- and infra others 0-4 696 (1.6) 649 (4.4) 58 (2.7) 1,403 (2.3) 98 (1.8) 6 (1.3) 5-9 780 (1.7) 703 (4.8) 53 (2.5) 1,536 (2.5) 113 (2.0) 8 (1.7) 10-14 1,273 (2.8) 489 (3.3) 77 (3.6) 1,839 (3.0) 159 (2.8) 9 (1.9) 15-19 1,463 (3.3) 361 (2.5) 104 (4.9) 1,928 (3.1) 265 (4.7) 17 (3.6) 20-24 1,736 (3.9) 428 (2.9) 78 (3.7) 2,242 (3.6) 376 (6.7) 25 (5.3) 25-29 1,855 (4.1) 535 (3.7) 80 (3.8) 2,470 (4.0) 388 (6.9) 26 (5.5) 30-34 2,005 (4.5) 588 (4.0) 80 (3.8) 2,673 (4.3) 383 (6.8) 24 (5.1) 35-39 2,545 (5.7) 822 (5.6) 120 (5.7) 3,487 (5.7) 423 (7.6) 35 (7.4) 40-44 3,195 (7.1) 1,075 (7.4) 148 (7.0) 4,418 (7.2) 472 (8.4) 40 (8.5) 45-49 3,894 (8.7) 1,414 (9.7) 217 (10.2) 5,525 (9.0) 560 (10.0) 43 (9.1) 50-54 4,497 (10.0) 1,678 (11.5) 210 (9.9) 6,385 (10.4) 540 (9.7) 38 (8.1) 55-59 4,883 (10.9) 1,653 (11.3) 250 (11.8) 6,786 (11.0) 483 (8.6) 56 (11.9) 60-64 4,963 (11.0) 1,518 (10.4) 204 (9.6) 6,685 (10.8) 492 (8.8) 41 (8.7) 65-69 4,751 (10.6) 1,301 (8.9) 223 (10.5) 6,275 (10.2) 418 (7.5) 47 (10.0) 70-6,410 (14.3) 1,414 (9.7) 221 (10.4) 8,045 (13.0) 426 (7.6) 56 (11.9) 44,946 (100.0) 14,628 (100.0) 2,123 (100.0) 61,697 (100.0) 5,596 (100.0) 471 (100.0) 338 100 22 460 49 8 2) All Glioma age supra- infrasupra- and infra others 0-4 365 (2.6) 529 (20.2) 28 (11.0) 922 (5.5) 10 (6.0) 4 (4.3) 5-9 297 (2.1) 543 (20.7) 19 (7.5) 859 (5.1) 19 (11.4) 3 (3.2) 10-14 393 (2.8) 342 (13.1) 18 (7.1) 753 (4.5) 15 (9.0) 4 (4.3) 15-19 415 (3.0) 168 (6.4) 23 (9.0) 606 (3.6) 13 (7.8) 3 (3.2) 20-24 485 (3.5) 127 (4.9) 17 (6.7) 629 (3.8) 9 (5.4) 2 (2.1) 25-29 607 (4.4) 109 (4.2) 12 (4.7) 728 (4.4) 11 (6.6) 3 (3.2) 30-34 726 (5.2) 87 (3.3) 13 (5.1) 826 (4.9) 15 (9.0) 3 (3.2) 35-39 911 (6.6) 103 (3.9) 13 (5.1) 1,027 (6.1) 9 (5.4) 4 (4.3) 40-44 1,066 (7.7) 84 (3.2) 13 (5.1) 1,163 (7.0) 8 (4.8) 13 (13.8) 45-49 1,120 (8.1) 91 (3.5) 19 (7.5) 1,230 (7.4) 14 (8.4) 7 (7.5) 50-54 1,266 (9.1) 77 (2.9) 15 (5.9) 1,358 (8.1) 15 (9.0) 8 (8.5) 55-59 1,386 (10.0) 101 (3.9) 16 (6.3) 1,503 (9.0) 11 (6.6) 12 (12.8) 60-64 1,493 (10.8) 73 (2.8) 14 (5.5) 1,580 (9.4) 8 (4.8) 3 (3.2) 65-69 1,346 (9.7) 79 (3.0) 18 (7.1) 1,443 (8.6) 5 (3.0) 13 (13.8) 70-1,988 (14.3) 107 (4.1) 17 (6.7) 2,112 (12.6) 5 (3.0) 12 (12.8) 13,864 (100.0) 2,620 (100.0) 255 (100.0) 16,739 (100.0) 167 (100.0) 94 (100.0) 106 28 2 136 1 2

14 3) All Primary Brain Tumors : Central or Lateral age right left right and left central others 0-4 271 (1.4) 264 (1.3) 146 (2.8) 747 (3.9) 1,428 (2.2) 59 (1.8) 20 (2.7) 5-9 241 (1.2) 283 (1.4) 122 (2.4) 946 (4.9) 1,592 (2.5) 48 (1.5) 17 (2.3) 10-14 342 (1.8) 339 (1.7) 147 (2.9) 1,084 (5.6) 1,912 (3.0) 78 (2.4) 17 (2.3) 15-19 372 (1.9) 380 (1.9) 172 (3.3) 1,124 (5.8) 2,048 (3.2) 124 (3.8) 38 (5.2) 20-24 462 (2.4) 461 (2.3) 173 (3.4) 1,296 (6.7) 2,392 (3.8) 224 (6.8) 27 (3.7) 25-29 614 (3.1) 598 (3.0) 198 (3.9) 1,218 (6.3) 2,628 (4.1) 226 (6.9) 30 (4.1) 30-34 721 (3.7) 767 (3.9) 191 (3.7) 1,148 (6.0) 2,827 (4.4) 216 (6.5) 37 (5.1) 35-39 1,054 (5.4) 1,072 (5.4) 296 (5.8) 1,244 (6.5) 3,666 (5.8) 232 (7.0) 47 (6.4) 40-44 1,388 (7.1) 1,473 (7.5) 328 (6.4) 1,412 (7.3) 4,601 (7.2) 273 (8.3) 56 (7.7) 45-49 1,870 (9.6) 1,817 (9.2) 440 (8.6) 1,613 (8.4) 5,740 (9.0) 331 (10.0) 57 (7.8) 50-54 2,219 (11.4) 2,195 (11.1) 476 (9.2) 1,657 (8.6) 6,547 (10.3) 351 (10.6) 65 (8.9) 55-59 2,290 (11.7) 2,415 (12.2) 586 (11.4) 1,649 (8.6) 6,940 (10.9) 304 (9.2) 81 (11.1) 60-64 2,393 (12.2) 2,324 (11.8) 609 (11.8) 1,534 (8.0) 6,860 (10.8) 276 (8.4) 82 (11.2) 65-69 2,276 (11.6) 2,261 (11.5) 561 (10.9) 1,315 (6.8) 6,413 (10.1) 274 (8.3) 53 (7.3) 70-00 3,037 (15.5) 3,097 (15.7) 704 (13.7) 1,301 (6.8) 8,139 (12.8) 285 (8.6) 103 (14.1) 19,550 (100.0) 19,746 (100.0) 5,149 (100.0) 19,288 (100.0) 63,733 (100.0) 3,301 (100.0) 730 (100.0) 126 148 48 162 484 20 13 6. General Features of Brain Tumors in Children : Age 0-14 1) Frequency of Primary Brain Tumors by Histology (1984-2000) histology number % histology number % glioblastoma 72 1.5 nonfuctioning pituitary adenoma 24 0.5 anaplastic ganglioglioma 10 0.2 HGH producing pituitary adenoma 19 0.4 sympathicoblastoma 1 0.0 PRL producing pituitary adenoma 25 0.5 neuroblastoma 30 0.6 ACTH producing pituitary adenoma 12 0.2 medulloepithelioma 5 0.1 other functioning pituitary adenoma 2 0.0 neuroepithelioma 3 0.1 malignant pituitary adenoma 1 0.0 polar spongioblastoma 27 0.5 craniopharyngioma 439 8.9 astrocytoma 917 18.6 glioma of pituitary region 3 0.1 anaplastic astrocytoma 264 5.4 teranoma 58 1.2 oligodendroglioma 39 0.8 malignant teranoma 72 1.5 malignant oligodendroblastoma 3 0.1 choriocarcinoma 33 0.7 mixed glioma 28 0.6 embryonal carcinoma 31 0.6 ependymoma 225 4.6 yolk sac tumor 26 0.5 anaplastic ependymoma 94 1.9 other germ cell tumor 72 1.5 plexus papilloma 78 1.6 dermoid 38 0.8 malignant plexus papilloma 17 0.3 epidermoid 36 0.7 glioblastoma 183 3.7 chordoma 14 0.3 medulloblastoma 593 12.0 malignant chordoma - (-) neurinoma (schwannoma) 40 0.8 tumor of bone and cartilage 64 1.3 von Recklinghausen's disease 33 0.7 lipoma 28 0.6 malignant neurinoma (schwannoma) 1 0.0 malignant lymphoma 17 0.3 meningioma 94 1.9 other sarcoma 27 0.5 malignant meningiona 8 0.2 primary malignant melanoma 2 0.0 hemangioblastoma 25 0.5 glioma ** 195 4.0 hemangiopericytoma 6 0.1 multiple 6 0.1 germinoma 462 9.4 others 320 6.5 pineocytoma 11 0.2 unclassified tumor 39 0.8 pineoblastoma 31 0.6 4,929 100.0 pituitary adenoma * 26 0.5 242 * number of the pituitary adenoma by classic classification ** glioma, not verified

15 2) Age and Sex Distribution of Primary Brain Tumors in Children (1984-2000) age male (%) female (%) (%) <1 172 (5.8) 183 (8.3) 355 (6.9) 1 187 (6.3) 133 (6.0) 320 (6.2) 2 146 (4.9) 119 (5.4) 265 (5.1) 3 142 (4.8) 123 (5.6) 265 (5.1) 4 170 (5.8) 132 (6.0) 302 (5.8) 5 191 (6.5) 149 (6.7) 340 (6.6) 6 159 (5.4) 143 (6.5) 302 (5.8) 7 166 (5.6) 136 (6.1) 302 (5.8) 8 196 (6.6) 160 (7.2) 356 (6.9) 9 213 (7.2) 144 (6.5) 357 (6.9) 10 221 (7.5) 141 (6.4) 362 (7.0) 11 207 (7.0) 139 (6.3) 346 (6.7) 12 238 (8.1) 178 (8.0) 416 (8.0) 13 271 (9.2) 163 (7.4) 434 (8.4) 14 276 (9.3) 173 (7.8) 449 (8.7) 2,955 (100.0) 2,216 (100.0) 5,171 (100.0) 3) Age Distribution of Supra or Infratentorial Tumors in Children (1984-2000) supra - and age supra- infra- infra others <1 199 (7.2) 96 (5.2) 23 (12.2) 318 (6.7) 37 (10.0) - (-) 1 119 (4.3) 170 (9.2) 12 (6.4) 301 (6.3) 19 (5.1) - (-) 2 121 (4.4) 120 (6.5) 11 (5.9) 252 (5.3) 12 (3.2) 1 (4.3) 3 126 (4.6) 113 (6.1) 6 (3.2) 245 (5.1) 17 (4.6) 3 (13.0) 4 131 (4.8) 150 (8.1) 6 (3.2) 287 (6.0) 13 (3.5) 2 (8.7) 5 149 (5.4) 155 (8.4) 16 (8.5) 320 (6.7) 18 (4.9) 2 (8.7) 6 137 (5.0) 145 (7.9) 4 (2.1) 286 (6.0) 13 (3.5) 3 (13.0) 7 120 (4.4) 148 (8.0) 12 (6.4) 280 (5.9) 20 (5.4) 2 (8.7) 8 181 (6.6) 136 (7.4) 12 (6.4) 329 (6.9) 26 (7.0) 1 (4.3) 9 193 (7.0) 119 (6.5) 9 (4.8) 321 (6.7) 36 (9.7) - (-) 10 202 (7.3) 120 (6.5) 10 (5.3) 332 (6.9) 28 (7.6) 2 (8.7) 11 217 (7.9) 91 (4.9) 13 (6.9) 321 (6.7) 23 (6.2) 2 (8.7) 12 278 (10.1) 95 (5.2) 15 (8.0) 388 (8.1) 28 (7.6) - (-) 13 297 (10.8) 85 (4.6) 19 (10.1) 401 (8.4) 29 (7.8) 4 (17.4) 14 279 (10.1) 98 (5.3) 20 (10.6) 397 (8.3) 51 (13.8) 1 (4.3) 2,749 (100.0) 1,841 (100.0) 188 (100.0) 4,778 (100.0) 370 (100.0) 23 (100.0) 4) Age Distribution of Tumors in Children by sites : Central or Lateral (1984-2000) age right left right and left central others <1 68 (8.0) 76 (8.6) 43 (10.4) 147 (5.3) 334 (6.8) 18 (9.7) 3 (5.6) 1 54 (6.3) 44 (5.0) 34 (8.2) 170 (6.1) 302 (6.1) 14 (7.6) 4 (7.4) 2 59 (6.9) 46 (5.2) 27 (6.5) 119 (4.3) 251 (5.1) 10 (5.4) 4 (7.4) 3 54 (6.3) 48 (5.4) 21 (5.1) 127 (4.6) 250 (5.1) 9 (4.9) 6 (11.1) 4 36 (4.2) 50 (5.6) 21 (5.1) 184 (6.6) 291 (5.9) 8 (4.3) 3 (5.6) 5 48 (5.6) 61 (6.9) 33 (8.0) 183 (6.6) 325 (6.6) 11 (5.9) 4 (7.4) 6 39 (4.6) 54 (6.1) 20 (4.8) 176 (6.3) 289 (5.9) 9 (4.9) 4 (7.4) 7 33 (3.9) 36 (4.1) 26 (6.3) 193 (6.9) 288 (5.8) 11 (5.9) 3 (5.6) 8 61 (7.1) 66 (7.4) 21 (5.1) 200 (7.2) 348 (7.1) 5 (2.7) 3 (5.6) 9 60 (7.0) 66 (7.4) 22 (5.3) 194 (7.0) 342 (6.9) 12 (6.5) 3 (5.6) 10 52 (6.1) 71 (8.0) 19 (4.6) 208 (7.5) 350 (7.1) 8 (4.3) 4 (7.4) 11 61 (7.1) 54 (6.1) 30 (7.2) 183 (6.6) 328 (6.7) 11 (5.9) 7 (13.0) 12 78 (9.1) 73 (8.2) 34 (8.2) 208 (7.5) 393 (8.0) 22 (11.9) 1 (1.9) 13 80 (9.4) 65 (7.3) 32 (7.7) 237 (8.5) 414 (8.4) 18 (9.7) 2 (3.7) 14 71 (8.3) 76 (8.6) 32 (7.7) 248 (8.9) 427 (8.7) 19 (10.3) 3 (5.6) 854 (100.0) 886 (100.0) 415 (100.0) 2,777 (100.0) 4,932 (100.0) 185 (100.0) 54 (100.0)

16 7. General Features of Primary Brain Tumors (1984-2000) 1) Months from Onset to Treatment month no. month no. month no. month no. year no. <1M 2,011 10 1,087 20 343 55-60 1,410 10 < 1,313 1 14,335 11 470 21 123 61-66 91 15 < 344 2 8,132 12 2,657 22 135 67-72 583 20 < 315 3 5,202 13 446 23 73 73-78 61 30 < 90 4 3,126 14 478 24 2,135 79-84 417 40 < 24 5 2,215 15 336 25-30 709 85-90 92 50 < 36 6 2,731 16 263 31-36 1,899 91-96 304 8,190 7 1,347 17 193 37-42 355 97-108 265 8 1,203 18 445 43-48 1,003 109-119 49 9 788 19 165 49-54 292 68,281 2) Diagnostic Methods surgical specimen 58,819 (86.1) CSF cell culture 118 (0.2) X-ray, Isotope 143 (0.2) clinical signs, symptoms 177 (0.3) autopsy 166 (0.2) CT 3,296 (4.8) MRI 3,846 (5.6) others 425 (0.6) 1,291 (1.9) 68,281 (100.0) 3) Existence of Malignant Neoplasms of Other Organ none 65,044 (95.3) others 1,661 (2.4) CNS 627 (0.9) 949 (1.4) 68,281 (100.0) 4) Clinical Grading no clinical symptoms 5,658 (8.4) subjective complaints only 15,375 (22.8) focal signs 35,084 (52.1) intracranial hypertension 7,690 (11.4) disturbance of consciousness 3,069 (4.6) coma 377 (0.6) respiratory impairment 80 (0.1) 67,333 (100.0) 948

17 5) Multiplicity 6) Location : Supra or Infratentorial single 64,899 (95.6) supratentorial 45,284 (66.8) multiple 2,811 (4.1) infratentorial 14,728 (21.7) other 212 (0.3) supra- & infra- 2,145 (3.2) 67,922 (100.0) others 5,645 (8.3) 359 67,802 (100.0) 479 7) Laterality 8) Location of Cerebral Hemispheric Tumors right 19,676 (29.1) nos 35,345 (73.4) left 19,894 (29.5) dorsal 2,142 (4.5) bilateral 5,197 (7.7) lateral 4,353 (9.1) central 19,450 (28.8) medial 5,597 (11.6) others 3,321 (4.9) ventoral 688 (1.4) 67,538 (100.0) 48,125 (100.0) 743 nos : not otherwise specified 2,211 9) Tumor Location (except Meningioma) frontal lobe 6,678 (13.6) pineal region 1,388 (2.8) tenporal lobe 3,673 (7.5) aqueduct 49 (0.1) parietal lobe 2,613 (5.3) cerebellar vermis 1,164 (2.4) occipital lobe 818 (1.7) cerebellar hemisphere 1,593 (3.2) diffuse 270 (0.6) fourth ventricle 660 (1.3) chiasmal region 11,191 (22.8) cerebello- pontine angle 6,927 (14.1) third ventricle, ant. 656 (1.3) caudal brain stem 1,170 (2.4) third ventricle, post. 187 (0.4) (pons and medulla) lateral ventricle 621 (1.3) optic nerve 206 (0.4) (ant. horn-body) calvarium 390 (0.8) lat. vent. (trigonum) 210 (0.4) skull base, medial 2,304 (4.7) lat. vent. (tenp. horn) 69 (0.1) skull base, paramedial 551 (1.1) corpus callosum and 583 (1.2) others 3,700 (7.5) septum pellucidum rostral brain stem and 1,457 (3.0) 49,128 (100.0) basal ganglia 1,208

18 10) Tumor Location on Meningioma parasagittal olfactory groove 626 (3.5) 1. anterior 1/3 675 (3.8) parasellar 2. middle 1/3 972 (5.5) 1. tuberculum sellae 987 (5.6) 3. posterior 1/3 385 (2.2) 2. planum sphenoidale 238 (1.3) 18 (0.1) 3. intrasellar 54 (0.3) falx 42 (0.2) 1. anterior 1/3 940 (5.3) middle fossa 441 (2.5) 2. middle 1/3 583 (3.3) ventricle 3. posterior 1/3 444 (2.5) 1. lateral v. 246 (1.4) 43 (0.2) 2. third v. 19 (0.1) convexity 3. fourth v. 13 (0.1) 1. frontal 2,537 (14.3) 2 (0.0) 2. temporal 537 (3.0) cerebello-pontine angle 1,166 (6.6) 3. parietal 1,154 (6.5) tentorium 1,315 (7.4) 4. occipital 234 (1.3) clivus 330 (1.9) 5. Sylvian fissure 49 (0.3) cerebellar convexity 404 (2.3) 40 (0.2) foramen magnum 193 (1.1) sphenoid ridge others 1,237 (7.0) 1. lateral 1/3 498 (2.8) 2. middle 1/3 418 (2.4) 3. medial 1/3 848 (4.8) 17,767 (100.0) 79 (0.4) 178 11) Tumor Character of Growth 12) Infiltration to Other Tissue Out of Brain diffuse solid 15,825 (24.5) none 43,727 (69.3) cystic 2,844 (4.4) arachnoid 2,862 (4.5) circumscribed solid 38,519 (59.5) dura 8,939 (14.2) cystic 7,518 (11.6) skull 2,117 (3.4) 64,706 (100.0) scalp 115 (0.2) 3,575 not otherwise specified 5,303 (8.4) 63,063 (100.0) 5,218 13) Extracranial Metastases 14) Tumor Size : Diameter none 62,231 (97.5) <0.5cm 1,129 (1.9) spinal 1,284 (2.0) 1 7,148 (11.8) others 308 (0.5) 2 14,528 (24.0) 63,823 (100.0) 3 16,414 (27.1) 4,458 4 10,327 (17.0) 5 6,141 (10.1) 6 2,614 (4.3) 7 831 (1.4) >8cm 1,491 (2.5) 60,623 (100.0) 7,658

19 8. Mode of Therapy (1984-2000) 1) Operation first (%) second (%) none 10,516 (12.9) 45,901 (91.3) decompression 1,519 (1.9) 408 (0.8) biopsy or partial 9,240 (11.3) 470 (0.9) 50% resected 4,623 (5.7) 422 (0.8) 75% resected 10,667 (13.1) 938 (1.9) 95% resected 16,701 (20.5) 1,190 (2.4) removal 28,340 (34.7) 939 (1.9) 81,606 (100.0) 50,268 (100.0) 1,238 265 2) Radiotherapy RADIATION MODE none 53,767 (65.7) none 53,767 (65.9) irradiated 28,071 (34.3) external irradiation 26,539 (32.5) internal irradiation 185 (0.2) others 1,138 (1.4) 81,838 (100.0) 81,629 (100.0) 1,006 1,215 3) Mode of Irradiation Co 60 6,145 (22.6) Linac 20,276 (74.4) β-tron 57 (0.2) Heavy particle 24 (0.1) Isotope 47 (0.2) others 705 (2.6) 27,254 (100.0) 817 4) Radio-Sensitizer none 24,342 (90.9) BUdR 84 (0.3) others 70 (0.3) anticancer drug 2,296 (8.6) 26,792 (100.0) 1,279

20 5) Radiation to Spinal Cord none 25,758 (94.8) irradiated 1,418 (5.2) 27,176 (100.0) 895 6) Total Dose of Irradiation 0-10(Gy) 331 (1.2) 20 1,661 (6.2) 30 2,169 (8.1) 40 3,494 (13.1) 50 10,003 (37.4) 60 7,966 (29.8) 70 792 (3.0) 80 139 (0.5) 80< 192 (0.7) 26,747 (100.0) 1,324 7) Chemotherapy none 66,428 (81.5) done 15,041 (18.5) 81,469 (100.0) 1,375 8) Chemotherapeutic Agents (1984-2000) chemotherapeutic agents first second third fourth Methotrexate 836 (5.7) 74 (0.9) 68 (2.6) 32 (5.6) 5-FU 577 (4.0) 154 (1.9) 29 (1.1) 8 (1.4) Endoxan 345 (2.4) 192 (2.3) 72 (2.7) 27 (4.7) MMC 145 (1.0) 81 (1.0) 28 (1.1) 2 (0.4) Vincristine 1,797 (12.3) 1,017 (12.4) 284 (10.7) 38 (6.6) BCNU 16 (0.1) 7 (0.1) 1 (0.0) - (-) CCNU 18 (0.1) 5 (0.1) 1 (0.0) 1 (0.2) Cyclocytidine 4 (0.0) 20 (0.2) 10 (0.4) 4 (0.7) Procarbazine 64 (0.4) 182 (2.2) 108 (4.1) 23 (4.0) Adriamycin 209 (1.4) 236 (2.9) 227 (8.5) 33 (5.7) Bleomycin 188 (1.3) 195 (2.4) 72 (2.7) 30 (5.2) Actinomycin-D 8 (0.1) 26 (0.3) 15 (0.6) 6 (1.0) Me-CCNU 13 (0.1) 4 (0.1) - (-) - (-) ACNU 5,888 (40.4) 1,503 (18.3) 237 (8.9) 22 (3.8) Tegafur 204 (1.4) 211 (2.6) 31 (1.2) 14 (2.4) Cisplatin 1,791 (12.3) 810 (9.9) 295 (11.1) 46 (8.0) MCNU 1,024 (7.0) 337 (4.1) 57 (2.1) 6 (1.0) VP-16 510 (3.5) 1,353 (16.5) 229 (8.6) 61 (10.6) IFN-β 52 (0.4) 83 (1.0) 30 (1.1) 3 (0.5) others 882 (6.1) 1,719 (20.9) 873 (32.7) 221 (38.3) 14,571 (100.0) 8,209 (100.0) 2,667 (100.0) 577 (100.0) 470 269 19 14

21 9) Performance State: Before Treatment *1 32,205 (39.9) 2 20,952 (25.9) 3 7,953 (9.8) 4 11,451 (14.2) 5 4,120 (5.1) 6 3,526 (4.4) 7 592 (0.7) 80,799 (100.0) 2,044 10) Performance State: After Treatment *1 38,307 (48.3) 2 16,319 (20.6) 3 7,353 (9.3) 4 8,160 (10.3) 5 2,773 (3.5) 6 2,879 (3.6) 7 3,546 (4.5) 79,337 (100.0) 2,710 * 1. Normal: No complaints; No evidence of disease 2. Normal activity with effort; some symptoms 3. Cares for self; Unable to carry on normal activity 4. Requires occasional assistance; Cares for most needs 5. Disabled; Requires special needs and assistance 6. Severely disabled; Hospitalized, death not imminent 7. Morbibund; Fatal processes are rapidly progressing 9. Unknown

22 9. General Features of Metastatic Brain Tumors (1984-2000) 1) Age distribution of Metastatic Tumors age male (%) female (%) (%) 0 2 (0.0) 3 (0.1) 5 (0.0) 1 2 (0.0) 4 (0.1) 6 (0.0) 2 3 (0.0) 7 (0.1) 10 (0.1) 3 9 (0.1) 1 (0.0) 10 (0.1) 4 8 (0.1) 2 (0.0) 10 (0.1) 05-09 16 (0.2) 14 (0.3) 30 (0.2) 10-14 13 (0.1) 7 (0.1) 20 (0.1) 15-19 22 (0.3) 12 (0.2) 34 (0.2) 20-24 35 (0.4) 23 (0.4) 58 (0.4) 25-29 44 (0.5) 40 (0.7) 84 (0.6) 30-34 70 (0.8) 103 (1.9) 173 (1.2) 35-39 155 (1.7) 212 (3.9) 367 (2.5) 40-44 329 (3.7) 374 (6.8) 703 (4.9) 45-49 549 (6.1) 569 (10.3) 1,118 (7.7) 50-54 873 (9.7) 683 (12.4) 1,556 (10.7) 55-59 1,310 (14.6) 724 (13.1) 2,034 (14.0) 60-64 1,612 (18.0) 815 (14.8) 2,427 (16.8) 65-69 1,658 (18.5) 725 (13.2) 2,383 (16.5) 70-74 1,316 (14.7) 646 (11.7) 1,962 (13.6) 75-79 679 (7.6) 382 (6.9) 1,061 (7.3) 80-84 220 (2.5) 125 (2.3) 345 (2.4) 85-89 42 (0.5) 34 (0.6) 76 (0.5) 90-94 3 (0.0) 7 (0.1) 10 (0.1) 95-00 1 (0.0) 1 (0.0) 2 (0.0) 8,971 (100.0) 5,513 (100.0) 14,484 (100.0) 48 31 79 2) Months from Onset to Surgery 3) Diagnostic Methods <1M 1,234 (9.4) 18 7 (0.1) surgical specimen 9,845 (68.2) 1 6,855 (52.5) 19 7 (0.1) CSF cell culture 244 (1.7) 2 2,280 (17.5) 20 14 (0.1) X-ray, Isotope 102 (0.7) 3 965 (7.4) 21 1 (0.0) symptoms 36 (0.3) 4 466 (3.6) 22 6 (0.1) autopsy 97 (0.7) 5 279 (2.1) 23 4 (0.0) CT 2,498 (17.3) 6 252 (1.9) 24 45 (0.3) MRI 1,438 (10.0) 7 125 (1.0) 25-30 25 (0.2) others 175 (1.2) 8 62 (0.5) 31-36 21 (0.2) 14,435 (100.0) 9 70 (0.5) 37-42 4 (0.0) 128 10 59 (0.5) 43-48 12 (0.1) 11 31 (0.2) 49-54 3 (0.0) 12 115 (0.9) 55-60 16 (0.1) 13 18 (0.1) 61-66 2 (0.0) 14 36 (0.3) 67-00 21 (0.2) 15 13 (0.1) 16 13 (0.1) 13,066 (100.0) 17 5 (0.0) 1,497

23 4) Months from Diagnosis of Primary Tumor to Diagnosis of Metasitatic Brain Tumor <1M 2,222 (20.3) 14 173 (1.6) 43-48 370 (3.4) 1 816 (7.5) 15 166 (1.5) 49-54 143 (1.3) 2 324 (3.0) 16 119 (1.1) 55-60 298 (2.7) 3 272 (2.5) 17 107 (1.0) 61-66 77 (0.7) 4 299 (2.7) 18 149 (1.4) 67-72 214 (2.0) 5 264 (2.4) 19 93 (0.9) 73-78 41 (0.4) 6 360 (3.3) 20 115 (1.1) 79-84 152 (1.4) 7 252 (2.3) 21 69 (0.6) 85-90 32 (0.3) 8 261 (2.4) 22 96 (0.9) 91-96 75 (0.7) 9 222 (2.0) 23 62 (0.6) 97-421 (3.9) 10 247 (2.3) 24 411 (3.8) 11 184 (1.7) 25-30 447 (4.1) 12 462 (4.2) 31-36 507 (4.6) 10,929 (100.0) 13 157 (1.4) 37-42 250 (2.3) 3,634 5) Clinical Grading no symptoms 650 (4.5) complaints omly 1,434 (10.0) focal signs 8,482 (59.0) increased ICP 2,582 (18.0) disturbance of consciousness 1,028 (7.2) coma 188 (1.3) respiratory impairment 23 (0.2) 14,387 (100.0) 176 6) Recurrence of Primary Tumor at The Time of Diagnosis of Metastatic Brain Tumor recurrence(-) 5,959 (57.3) recurrence(+) 4,444 (42.7) 10,403 (100.0) 4,160 7) Metasta sis to Other Organs metastasis(-) 6,454 (56.3) metastasis(+) 5,005 (43.7) 11,459 (100.0) 3,104

24 8) Mode of Metastasis 11) Location of Metastasis solitary 8,614 (59.6) frontal lobe 2,415 (17.4) multiple 5,450 (37.7) temporal lobe 728 (5.3) mening. ca. 401 (2.8) parietal lobe 1,616 (11.6) 14,465 (100.0) occipital lobe 949 (6.8) 98 diffuse 31 (0.2) chiasmal region 53 (0.4) third ventricle, ant. 15 (0.1) third ventricle, post. 12 (0.1) 9) Location : Supra or Infratentorial lateral ventricle 33 (0.2) (ant.horn-body) supratentorial 9,504 (66.0) lat. vent. (trigonum) 27 (0.2) infratentorial 2,059 (14.3) lat. vent. (temp.horn) 93 (0.7) supra- & infratentorial 2,227 (15.5) corpus callosum and 152 (1.1) others 613 (4.3) septum pellucidum 14,403 (100.0) rostral brain stem 218 (1.6) 160 and basal ganglia pineal region 45 (0.3) aqueduct 5 (0.0) cerebeller vermis 307 (2.2) 10) Laterallity cerebellar hemispher 1,300 (9.4) fourth ventricle 21 (0.2) right 4,578 (32.0) cerebello-pontine angle 101 (0.7) left 4,459 (31.2) caudal brain stem 59 (0.4) bilateral 3,166 (22.2) (pons and medulla) central 780 (5.5) optic nerve 14 (0.1) not otherwise specified 1,312 (9.2) calvarium 270 (2.0) 14,295 (100.0) skull-base, medial 182 (1.3) 268 skull-base, paramedial 183 (1.3) others 5,050 (36.4) 13,879 (100.0) 684

25 12) Frequency of Tumors by Primary Cancer 15) Mode of Operation for Primary Cancer lung 6,947 (51.9) none 6,448 (48.8) breast 1,246 (9.3) radical 5,292 (40.1) homatopoietic 55 (0.4) non-radical 1,469 (11.1) bone 85 (0.6) 13,209 (100.0) soft tissue 80 (0.6) 1,354 skin 136 (1.0) stomach 646 (4.8) intestine 627 (4.7) 16) Histological Diagnosis of Metastatic rectum 726 (5.4) Brain Tumors liver 278 (2.1) spleen 10 (0.1) adeno 7,394 (59.3) head and neck 433 (3.2) squamous 1,615 (13.0) thyroid 192 (1.4) undifferentiated 150 (1.2) testis 74 (0.6) oat(small) cell 765 (6.1) bladder 101 (0.8) transitional 96 (0.8) uterus 226 (1.7) AML 10 (0.1) ovary 120 (0.9) ALL 16 (0.1) kidney 715 (5.3) CML 3 (0.0) eye 30 (0.2) CLL 2 (0.0) lymph node 96 (0.7) other L 11 (0.1) nervous tissue 31 (0.2) sarcoma 173 (1.4) others 539 (4.0) retinoblastoma 10 (0.1) 13,393 (100.0) neuroblastoma 31 (0.3) 1,170 melanoma 182 (1.5) lymphoma 211 (1.7) clear cell 386 (3.1) 13) Mode of Treatment for Primary Cancer large cell 424 (3.4) others 985 (7.9) none 3,895 (28.3) 12,464 (100.0) ope, rad, chem 1,620 (11.8) 2,099 ope, rad 662 (4.8) ope, chem 2,401 (17.5) rad, chem 676 (4.9) ope 2,785 (20.3) rad 457 (3.3) chem 1,134 (8.2) others 126 (0.9) chem : chemotherapy 13,756 (100.0) 807 14) Hormonal Treatment for Primary Cancer none 12,647 (96.1) oophorectomy 59 (0.5) adrenalectomy 6 (0.1) hypophysectomy 4 (0.0) steroid 207 (1.6) others 235 (1.8) 13,158 (100.0) 1,405